Summary
Introduction: Sotalol and verapamil alone reduce reentry incidence during ventricular fibrillation (VF). We tested whether the combination of these two drugs had a synergistic effect on initiation, maintenance, and termination of VF.
Methods:
Six open-chest pigs received intravenous sotalol (1.5 mg/kg) followed by verapamil (0.136 mg/kg). VF threshold (VFT) was determined by a burst pacing protocol. Two 20 seconds episodes of VF were recorded from a 21 × 24 unipolar electrode plaque on the lateral posterior left ventricular epicardium before and after each drug. VF activation patterns were quantified. The duration of long duration VF (LDVF) maintenance was compared to our previously published data.
Results: Sotalol alone and combined with verapamil significantly increased the VFT from 12.3 ± 4.1 to 20.3 ± 7.1 and 26.7 ± 8.6 mA compared with baseline (P < .05).
Sotalol decreased the number of wavefronts by 20%, VF activation rate by 17% and conduction velocity 11%, while the addition of verapamil neutralized these effects.
Addition of verapamil to sotalol further decreased the fractionation incidence from 14% to 29% and multiplicity from 24% to 31% compared with baseline. The combination of the two drugs increased the VF cycle length, decreased synchronicity, increased regularity index and shortened the duration of LDVF maintenance compared with our previous data of verapamil alone or no drug. Synchronicity index was lower and regularity index was higher in animals in which VF spontaneously terminated earlier than 10 minutes than in animals in which VF terminated longer than 10 minutes.
Conclusion:
The combination of sotalol and verapamil increased VFT but accelerated LDVF termination.
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| INTRODUC TI ON
Ventricular fibrillation (VF) is the main cause of sudden cardiac death in developed countries. 1 Currently, electrical defibrillation is the only proven effective therapy to terminate VF. In acute ventricular fibrillation, drugs are used after defibrillation attempts to restore normal rhythm. Drugs can also be used on a long-term basis in patients who refuse an implantable cardioverter-defibrillator (ICD) or who are not candidates for an ICD.
Generally, reentry is thought to play an important role in VF initiation and maintenance of short duration of VF. 2, 3 Separately, we have shown that sotalol 4 and verapamil 5 significantly reduce the incidence of reentry by different mechanisms. Sotalol reduces the incidence of reentry by flattening the slope of the restitution curve, decreasing the dispersion of refractoriness and prolongation of refractoriness. Verapamil terminates reentry in the in vivo pig model by both increasing reentrant velocity and decreasing the refractory period, but mainly by increasing the reentrant velocity so that the propagation of reentrant wavefronts is blocked in the reentrant pathway. When sotalol was added to reduce the VF conduction velocity before verapamil was added, the subsequent addition of verapamil did not accelerate the conduction velocity to a degree to further decrease the reentrant incidence. 5 However, many other antiarrhythmic mechanisms of the combination of both drugs on VF initiation, termination as well as maintenance are unknown. As both drugs flatten the slope of the restitution curve and reduce the dispersion of refractoriness, one hypothesis of the study was that the combination of these two drugs will increase the threshold to initiate VF.
In addition, over the past 20 years, the incidence of out-ofhospital VF has declined compared with asystole as the first recorded rhythm during sudden cardiac arrest (SCA). 6, 7 Some individuals seen in asystole may have earlier been in VF, but the VF may have degenerated into asystole by the time the first responders arrived. Many patients with a high risk of sudden cardiac death are now under the treatment of an antiarrhythmia drug and some drugs have been shown to cause a more rapid progression from VF into asystole. This could explain the decline of the incidence of out-of-hospital VF. As sotalol decreases the conduction velocity and verapamil inhibits the L-type Ca ++ channels, both effects could work together to terminate late VF. Another hypothesis tested in the study is that the combination of these two drugs causes the termination of VF earlier than with monotherapy alone. 
| ME THODS

| Animal preparation
We used the same methods as previously reported. 5, 9 These two previous studies served as a comparison for this study. Six pigs (40 ± 4 kg, mean ± SD) were injected intramuscularly with Telazol 
| Measurement of refractory period
The ventricular effective refractory period (VERP) was determined using a decremental S1-S2 pacing protocol from the two middle electrodes of the plaque on the epicardium. Both S1 and S2 stimuli (5 ms duration) were given at twice diastolic threshold.
The S1-S1 interval was 300 ms (10 beats), and the initial S1-S2
interval was 280 ms. The S1-S2 interval was decreased in 10 ms decrements until the S2 did not capture the ventricles on the ECG.
Then the S1-S2 interval was reset to 10 ms more than this noncapture interval and was decreased in 2 ms decrements until S2 again failed to capture the ventricles. This S1-S2 interval was defined as the VERP.
| Determination of ventricular fibrillation threshold (VFT)
VFT was performed by pacing at the same site as measurement of 
| Conduction time (CT) and conduction velocity (V)
The activation time of each channel at each pacing beat was defined as the instant when the most negative 1st order temporal derivative of voltage recording was reached. If the most negative derivative of the recording was not more negative than −0.5 V/s, no activation time was assigned and this electrode recording was excluded from the calculation for this paced beat. We noted that the extracellular recordings could be affected by 60 Hz noise artifacts, which could shift the time of the maximum downslope. To reduce the effect of these artifacts, the activation time of each channel was averaged with its 8 neighboring channels to represent the activation time at each electrode. For channels located at the boundary of the plaque, the number of neighboring channels was correspondingly reduced.
Conduction time (CT) of each electrode was defined as the interval between the activation time of the pacing electrode and measured electrode.
| Activation-recovery interval (ARI) measurements
The activation-recovery interval (ARI) was determined as an estimate of the action potential duration (APD) and, hence, the refractory period. 4 ,11 A 15-point quadratic differentiating filter was applied to determine the first derivatives of the extracellular potentials and to minimize the interference from noise. Activation time in the unipolar electrograms was defined as the steepest downslope of the QRS complex and recovery time as the fastest upslope of the T wave. The ARI was defined as the interval between the activation time and the recovery time.
| VF induction and termination
Any VF induced during the VFT determination and S1-S1 pacing protocol was used for VF analysis. If no VF was induced during S1-S1
pacing protocol, it was induced by a 9 V battery applied briefly to the right ventricle. Each VF episode was mapped for 20 seconds before it was halted by a 400-600 V biphasic shock (6/4 milliseconds) de- 
| Quantitative analysis of VF activation
Quantitative analysis of VF activation patterns was performed on a Linux system computer using algorithms discussed in detail elsewhere. 12, 13 Specifically, from the recordings made during the first 20 seconds of each VF episode, we defined the effects of sotalol separately and in combination with verapamil on the 5 quantitative VF parameters as follows: (1) number of wavefronts; (2) fractionation incidence; (3) block incidence; (4) multiplicity; and (5) activation rate.
To investigate the LDVF, the 10 minutes of VF were divided into 300 2-second episodes. For each episode, activation was identified as the 9-point dV/dt 14 of the recordings that reached a minimum of more than −0.3 mV/ms. To quantify the organization level of the LDVF, we defined a synchronicity index (syn-idx) and a regularity index (reg-idx) for each 2-second episode. 
| Statistical analysis
Results are expressed as mean ± SD. All VF variables were compared before and after sotalol administration and after the combination of sotalol and verapamil using multivariate analysis of variance (MANOVA) with repeated measures to test for differences between baseline and treatments. When differences were found, individual differences were determined with the Tukey test.
Dispersion of refractoriness and CV were quantified using the rela- . For all analyses, P < .05 was considered statistically significant.
| RE SULTS
| VERP
Compared to baseline, sotalol significantly prolonged the VERP by 17% (200 ± 17 milliseconds, 233 ± 23 milliseconds, P < .001). The combination of sotalol with verapamil slightly shortened VERP compared to sotalol alone (220 ± 21 milliseconds vs 233 ± 23 milliseconds, P = NS). Also, the VERP after the combination of sotalol and verapamil was not significantly longer than VERP at baseline (P = NS).
| VFT
Sotalol significantly increased the VFT from 12.3 ± 4.1 mA at baseline to 20.3 ± 7.1 mA (P = .02). The combination of sotalol and verapamil further increased the VFT to 26.7 ± 8.6 mA (P = .003) compared to baseline.
| Effects of sotalol on ARI and CV
Compared to baseline, sotalol significantly prolonged ARI by 12%
and decreased CV by 11% at PCL of 300 milliseconds (Table 1) .
Sotalol alone significantly reduced the relative dispersion of ARI by 38%, however, it did not significantly alter the dispersion of CV.
Adding verapamil to sotalol decreased the ARI by 19% compared with sotalol alone, the drug combination also further reduced the relative dispersion of ARI by 8%. Adding verapamil to sotalol significantly reduced the dispersion of CV by 18%.
| Quantitative analysis of short duration VF activation patterns
Quantitative data from all 1 second intervals of VF were pooled in Table 2 . Examples of VF activation sequences at baseline, after sotalol and after the combination of sotalol and verapamil are shown in Figure 1 .
Both sotalol and verapamil decreased fractionation incidence and multiplicity during VF, thus the combination of the two drugs further decreased fractionation incidence and multiplicity (Table 2) .
Sotalol decreased the number of wavefront, activation rate, and conduction velocity, while verapamil increased those parameters, net effects of the combination of these two drugs is toward to decrease the number of wavefront, activation rate, and conduction velocity ( Table 2 ).
| Long duration of ventricular fibrillation
| VF cycle length and duration of VF from induction to spontaneous termination
When compared with previous control and verapamil alone animals, the combination of verapamil and sotalol significantly increased the VF cycle length during the majority of the entire duration of the VF episode (Figure 2A) . No VF spontaneously terminated within 10 minutes in the previous control group without any antiarrhythmia drug administrated. 9 There was one animal in the previous study with verapamil in which VF spontaneously terminated at 8 minutes. Compared with our previous studies, VF spontaneously terminated within 10 minutes in one of the 6 pigs with verapamil only and no VF spontaneously terminated within 10 minutes in 6 pigs without antiarrhythmic drug (Table 3 ).
In the sotalol and verapamil combination group, the 2 animals with VF duration of 10 minutes had the shortest VF cycle length ( Figure 4A ). The shorter the duration of VF was, the longer the VF cycle length was. The synchronicity index was lower in animals in which the VF terminated before 10 minutes ( Figure 4B ). Immediately before each early VF terminated, we observed that there was a substantial increase in the regularity index ( Figure 4C ). 
| D ISCUSS I ON
The main findings of this study are: (1) Both sotalol alone and in combination with verapamil significantly increased VFT; (2) The synergic effects in reduction of fractionation and multiplicity by combination of the two drugs resulted in VF more organization; (3) However, the combination of these two drugs could accelerate the progression of VF from onset to spontaneous termination with asystole in swine.
| The effects of sotalol and verapamil on the electrical induction of VF
Since the first demonstration of VF induction by a single electrical shock delivered late in systole to the frog's ventricle, 16 Sotalol and verapamil were also demonstrated to have a synergistic effect in reducing the dispersion of ARI and conduction velocity measured during pacing in this study, which put the heart tissue into a more homogenous state, decreased the vulnerability of the heart to convert from VT, and thus increased the VFT.
| The effects of sotalol with verapamil on the progression of LDVF
While VF is the most commonly witnessed arrhythmia at the time of SCD, 23 in the last two decades the incidence of out-of-hospital VF has declined compared with asystole as the initially recorded rhythm. 6, 7 Multiple factors, such as increased age of the victims, severe underlying disease, antiarrhythmia drug use, cardiac pump failure without an arrhythmic event, and an increase in implantable cardioverter-defibrillator use to prevent VF in high risk patients, might all be related to this relative decrease in the incidence of finding patients in VF.
Recently, Wang et al 24 described that the drugs (beta-blockers and angiotensin converting enzyme inhibitors) widely used in primary and secondary coronary artery disease prevention strategies F I G U R E 2 Evolution of mean CL, synchronicity index (synidx), and regularity index (reg-idx) as VF progressed. A, VF-CL is significantly increased by the combination of verapamil and sotalol during the entire duration of the VF episode. The syn-idx is slightly but significantly lower during the first 300 s of VF in the drug combination group (B) when compared with control and verapamil alone groups. C, The reg-idx in the drug combination group is significantly higher during the first 300 s of VF when compared with the control group and verapamil alone group TA B L E 3 Duration of VF from initiation to spontaneous termination in swine hearts We defined the syn-idx and reg-idx in our previous endocardial mapping study to quantitatively describe canine endocardial electrical synchrony during LDVF. 15 We demonstrated that during the endocardial electrical synchrony of LDVF, the endocardium was excited almost simultaneously and that Purkinje activation played an important role in this endocardial electrical synchrony. Purkinje activation was registered in 6% of electrodes in the porcine epicardial layer, which differentiated the porcine epicardial activation patterns from canine. 27 We employed the syn-idx and reg-idx on pig epicardial mapping data to measure the spatial-temporal complexity of activation waveforms during LDVF. The lower syn-idx in the drug combination group indicates that the epicardium activated more synchronously than with verapamil alone or without any drug.
It is interesting that in the drug combination group, the four animals that spontaneously terminated VF before 10 minutes also showed a lower syn-idx than the other 2 animals in which VF lasted 10 minutes. Reg-idx was higher in the drug combination group than in the other two groups. The 4 animals in the drug combination group with early termination of VF also had a higher reg-idx than the other 2 animals. We observed that there was sudden and extreme reg-idx variation per second before each VF termination. The effects of sotalol in decreasing conduction velocity and increasing refractoriness combined with the effects of verapamil in inhibiting Ca ++ slow inward current which may inhibit the wavefronts propagation and divide the activation in many small areas in ventricles with a very slow rate. Some area might be triggered by EAD or DAD with abrupt increased activation rate before VF activation were terminated in the whole heart.
| Study limitations
There are several limitations in this study. We only investigated the effects of sotalol and verapamil at a fixed dosage. Therefore, the dose-dependent effect of the combination on VF activation patterns was not detected. The current study was conducted in healthy swine hearts, while VF usually occurs in diseased hearts. Many pathological changes will impact the effect of antiarrhythmic drugs on the heart. Whether the same effects are associated with myocardial infarction or heart failure should be examined in future studies. While the defibrillation threshold (DFT) after monotherapy of these two drugs has been investigated, the effects of combinations of drugs on the DFT should also be investigated in future studies. As with all animal studies, further studies in humans are required before the combinative therapy of intravenous sotalol and verapamil will be applied in the clinical settings. 
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